Literature DB >> 20826824

Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Ilja Bontjer1, Mark Melchers, Dirk Eggink, Kathryn David, John P Moore, Ben Berkhout, Rogier W Sanders.   

Abstract

The envelope glycoproteins (Env) are the focus of HIV-1 vaccine development strategies based on the induction of humoral immunity, but the mechanisms the virus has evolved to limit the induction and binding of neutralizing antibodies (NAbs) constitute substantial obstacles. Conserved neutralization epitopes are shielded by variable regions and carbohydrates, so one strategy to increase their exposure and, it is hoped, their immunogenicity is to delete the overlying variable loops. However, deleting the variable regions from Env trimers can be problematic, because hydrophobic patches that are normally solvent-inaccessible now become exposed, causing protein misfolding or aggregation, for example. Here, we describe the construction and characterization of recombinant gp140 trimers lacking variable domains 1 and 2 (ΔV1V2). The design of the trimers was guided by HIV-1 evolution studies that identified compensatory changes in V1V2-deleted but functional Env proteins (Bontjer, I., Land, A., Eggink, D., Verkade, E., Tuin, K., Baldwin, C., Pollakis, G., Paxton, W. A., Braakman, I., Berkhout, B., and Sanders, R. W. (2009) J. Virol. 83, 368-383). We now show that specific compensatory changes improved the function of ΔV1V2 Env proteins and hence HIV-1 replication. The changes acted by reducing the exposure of a hydrophobic surface either by replacing a hydrophobic residue with a hydrophilic one or by covering the surface with a glycan. The compensatory changes allowed the efficient expression of well folded, soluble gp140 trimers derived from various HIV-1 isolates. The evolved ΔV1V2 Env viruses were extremely sensitive to NAbs, indicating that neutralization epitopes are well exposed, which was confirmed by studies of NAb binding to the soluble ΔV1V2 gp140 trimers. These evolved ΔV1V2 trimers could be useful reagents for immunogenicity and structural studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826824      PMCID: PMC2978575          DOI: 10.1074/jbc.M110.156588

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  84 in total

1.  Antigenic variation in gp120s from molecular clones of HIV-1 LAI.

Authors:  J P Moore; H Yoshiyama; D D Ho; J E Robinson; J Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  1993-12       Impact factor: 2.205

2.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

Authors:  T Muster; R Guinea; A Trkola; M Purtscher; A Klima; F Steindl; P Palese; H Katinger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

3.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

Authors:  L Wu; N P Gerard; R Wyatt; H Choe; C Parolin; N Ruffing; A Borsetti; A A Cardoso; E Desjardin; W Newman; C Gerard; J Sodroski
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

4.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

5.  Immunogenicity of full length and truncated forms of the human immunodeficiency virus type I envelope glycoprotein.

Authors:  J A McKeating; C Shotton; S Jeffs; C Palmer; A Hammond; J Lewis; K Oliver; J May; P Balfe
Journal:  Immunol Lett       Date:  1996-06       Impact factor: 3.685

6.  Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.

Authors:  G P Allaway; A M Ryder; G A Beaudry; P J Maddon
Journal:  AIDS Res Hum Retroviruses       Date:  1993-07       Impact factor: 2.205

7.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

8.  Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D.

Authors:  A J Conley; M K Gorny; J A Kessler; L J Boots; M Ossorio-Castro; S Koenig; D W Lineberger; E A Emini; C Williams; S Zolla-Pazner
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

9.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more
  18 in total

1.  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.

Authors:  Thijs van Montfort; Mark Melchers; Gözde Isik; Sergey Menis; Po-Ssu Huang; Katie Matthews; Elizabeth Michael; Ben Berkhout; William R Schief; John P Moore; Rogier W Sanders
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

Review 2.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

3.  Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.

Authors:  Emilia Falkowska; Khoa M Le; Alejandra Ramos; Katie J Doores; Jeong Hyun Lee; Claudia Blattner; Alejandro Ramirez; Ronald Derking; Marit J van Gils; Chi-Hui Liang; Ryan Mcbride; Benjamin von Bredow; Sachin S Shivatare; Chung-Yi Wu; Po-Ying Chan-Hui; Yan Liu; Ten Feizi; Michael B Zwick; Wayne C Koff; Michael S Seaman; Kristine Swiderek; John P Moore; David Evans; James C Paulson; Chi-Huey Wong; Andrew B Ward; Ian A Wilson; Rogier W Sanders; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2014-04-24       Impact factor: 31.745

4.  Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1.

Authors:  Shi-Hua Xiang
Journal:  Curr HIV Res       Date:  2013-09       Impact factor: 1.581

5.  Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.

Authors:  Per Johan Klasse; Rafael S Depetris; Robert Pejchal; Jean-Philippe Julien; Reza Khayat; Jeong Hyun Lee; Andre J Marozsan; Albert Cupo; Nicolette Cocco; Jacob Korzun; Anila Yasmeen; Andrew B Ward; Ian A Wilson; Rogier W Sanders; John P Moore
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

6.  Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.

Authors:  Mark Melchers; Ilja Bontjer; Tommy Tong; Nancy P Y Chung; Per Johan Klasse; Dirk Eggink; David C Montefiori; Maurizio Gentile; Andrea Cerutti; William C Olson; Ben Berkhout; James M Binley; John P Moore; Rogier W Sanders
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

7.  An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells.

Authors:  Gözde Isik; Nancy P Y Chung; Thijs van Montfort; Sergey Menis; Katie Matthews; William R Schief; John P Moore; Rogier W Sanders
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

8.  Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.

Authors:  Gözde Isik; Thijs van Montfort; Nancy P Y Chung; John P Moore; Rogier W Sanders
Journal:  J Immunol       Date:  2014-04-11       Impact factor: 5.422

9.  Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.

Authors:  Ilja Bontjer; Mark Melchers; Tommy Tong; Thijs van Montfort; Dirk Eggink; David Montefiori; William C Olson; John P Moore; James M Binley; Ben Berkhout; Rogier W Sanders
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

10.  Chimeric HIV-1 envelope glycoproteins with potent intrinsic granulocyte-macrophage colony-stimulating factor (GM-CSF) activity.

Authors:  Gözde Isik; Thijs van Montfort; Maikel Boot; Viviana Cobos Jiménez; Neeltje A Kootstra; Rogier W Sanders
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.